

# News Releases

All Years



Search

GO

[Advanced Search](#)

**Nov 6, 2019**

## **Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting**

**- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...

**Nov 5, 2019**

## **Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update**

**- Andexxa®/Ondexxya® Net Product Revenues of \$35.7 million, a 32% Increase Over the Prior Quarter -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...

**Nov 1, 2019**

## **Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant...

**Oct 28, 2019**

## **Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding**

**- Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding -**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b/4 trial of its Factor Xa inhibitor...

**Oct 15, 2019**

## **Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019**

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019,...

**Sep 19, 2019**

## **Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors**

Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...

**Aug 22, 2019**

## **Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

**Aug 13, 2019**

**Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock**

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of \$28.00 per share. In...

**Aug 12, 2019**

**Portola Pharmaceuticals Announces Proposed Offering of Common Stock**

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, \$200 million of its common stock in an underwritten public offering. The...

**Aug 7, 2019**

**Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update**

**- Second Quarter Revenues of \$28.4 Million; Andexxa® Net Product Revenues Grow to \$27.1 Million**  
-

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update. "This is our fifth consecutive quarter of...

Show 10  per  
page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [25](#) 



<https://investors.portola.com/news-releases?l=10>